advertising Subscribe Newsletter About Us Home

 

Current Issue
Exclusives
Daily News
Datebook
Recipes


Editorial Calendar
Advisory Board
Writers' Guidelines
Contact Us


To be seventy years young is sometimes far more cheerful and hopeful than to
be forty years old.”

Oliver Wendell Holmes (1841-1935)



Home » Daily News

Jan. 10 - Reversal Of Alzheimer's Symptoms Within Minutes

An extraordinary new scientific study, which for the first time documents marked improvement in Alzheimer's disease within minutes of administration of a therapeutic molecule, has just been published in the Journal of Neuroinflammation.

This new study highlights the importance of certain soluble proteins, called cytokines, in Alzheimer's disease. The study focuses on one of these cytokines, tumor necrosis factor-alpha(TNF), a critical component of the brain's immune system. Normally, TNF finely regulates the transmission of neural impulses in the brain. The authors hypothesized that elevated levels of TNF in Alzheimer's disease interfere with this regulation. To reduce elevated TNF, the authors gave patients an injection of an anti-TNF therapeutic called etanercept. Excess TNF-alpha has been documented in the cerebrospinal fluid of patients with Alzheimer's.

The new study documents a dramatic and unprecedented therapeutic effect in an Alzheimer's patient: improvement within minutes following delivery of perispinal etanercept, which is etanercept given by injection in the spine. Etanercept (trade name Enbrel) binds and inactivates excess TNF. Etanercept is FDA approved to treat a number of immune-mediated disorders and is used off label in the study.

The use of anti-TNF therapeutics as a new treatment choice for many diseases, such as rheumatoid arthritis and potentially even Alzheimer's, was recently chosen as one of the top 10 health stories of 2007 by the Harvard Health Letter.

"It is unprecedented that we can see cognitive and behavioral improvement in a patient with established dementia within minutes of therapeutic intervention," said Sue Griffin, PhD."This gives all of us in Alzheimer's research a tremendous new clue about new avenues of research, which is so exciting and so needed in the field of Alzheimer's. Even though this report predominantly discusses a single patient, it is of significant scientific interest because of the potential insight it may give into the processes involved in the brain dysfunction of Alzheimer's."

Source: University of Arkansas for Medical Sciences

 

(View the Daily News Archive)




Copyright © 2008 Great Valley Publishing Co., Inc.
3801 Schuylkill Rd • Spring City, PA 19475
Publishers of Aging Well
All rights reserved.